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ABSTRACT 15 
Our previous study demonstrated that lignan metabolites enterolactone and enterodiol 16 
inhibited colonic cancer cell growth by inducing cell cycle arrest and apoptosis. However, the 17 
dietary lignans are naturally present as glycoside precursors such as secoisolariciresinol 18 
diglucoside (SDG) that has not been evaluated yet. This study is thus to test a hypothesis that the 19 
dietary SDG might have a different impact from its metabolites in human colonic SW480 cancer 20 
cells. Treatment with SDG at 0-40 µM up to 48 hrs resulted in a dose- and time-dependent 21 
decrease in cell numbers, which was comparable to enterolactone. The cell growth inhibited by 22 
SDG appeared not to be mediated by cytotoxicity, but cytostatic mechanism with an increase of 23 
cyclin A expression. Furthermore, HPLC analysis indicated SDG in the media was much more 24 
stable than enterolactone (95% of SDG survival vs. 57% of enterolactone after 48-hr treatment). 25 
When the cells were treated with either enterolactone or SDG at 40 µM for 48 hrs, the 26 
intracellular levels of enterolactone as measured by HPLC-MS/ESI were about 8.3 x 10-8 27 
nmol/cell, but intracellular SDG or potential metabolites were undetectable. Taken together, 28 
SDG demonstrated similar effects on cell growth, cytotoxicity, and cell cycle arrest when 29 
compared with its metabolite enterolactone. However, the reliable stability and undetectable 30 
intracellular SDG in treated cells may suggest that a metabolism of SDG, if exposed directly to 31 
the colonic cells, could be different from the known degradation by microorganisms in human 32 
gut. 33 
Keywords: Lignans, secoisolariciresinol diglucoside, enterolactone, cancer prevention, SW480 34 
cells35 
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1. Introduction 36 
Potential cancer prevention by dietary lignan glycoside, i.e., secoisolariciresinol 37 
diglucoside (SDG), has been suggested to be mediated through its metabolites, enterolactone and 38 
enterodiol [1-5]. The chemical structures of SDG and its mammalian metabolite enterolactone 39 
are shown in Figure 1. Enterolactone and enterodiol are anaerobically formed via colonic 40 
bacterial fermentation [6-7]. Besides the bacterial fermentation, enterolactone and enterodiol can 41 
also be formed by other cell organelles such as a study that showed liver microsomes could 42 
generate lignan aglycones [8]. 43 
Many studies show that SDG has cancer preventive properties in animal models. Our 44 
previous study demonstrated that SDG levels in wheat bran from various wheat cultivars were 45 
correlated to antitumor activities in APC-Min mice [9]. We also found that dietary SDG at 46 
0.01% significantly reduced azoxymethane-induced formation of aberrant crypt foci in F344 rats 47 
[10]. In addition, we have shown that enterolactone and enterodiol or both in combinations 48 
inhibit human cancer cell growth through inducing S-phase cell cycle arrest and apoptosis [9]. 49 
Experimental animal studies by others show that dietary supplementation with 73-293 µmol/kg 50 
SDG inhibits experimental metastasis of B16BL6 murine melanoma cells in C57BL/6 mice [11]. 51 
However, no in vitro studies have been done to specify cancer preventive property of SDG, 52 
although SDG metabolites, enterolactone and enterodiol, have been intensively investigated [12-53 
18]. Therefore, we hypothesized that the dietary SDG might have a different impact from its 54 
metabolites in human colonic SW480 cancer cells.  55 
The objective in this study is to determine the cancer preventive effects of SDG in human 56 
colon cancer SW480 cells. The effects of SDG on cellular growth and the underlying 57 
mechanisms regarding cytotoxicity and cell cycle interruption were studied and compared with 58 
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its metabolite enterolactone. SDG was also investigated for stability in the media when compared 59 
to enterolactone. Furthermore, HPLC- MS/ESI was used to evaluate whether SDG were taken up 60 
intracellularly into the cells, which may provide insight into its bioavailability and cancer 61 
preventive impact. 62 
2. Methods and materials  63 
2.1. Cell culture and treatments 64 
The human colon cancer SW480 cells were purchased from the American Type Culture 65 
Collection (Rockville, MD), and cultured in the Dulbecco’s Modified Eagle Media supplemented 66 
with 10% fetal bovine serum and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis MO). 67 
The cells were cultured in either 6-well plates or 200 mL volumetric flasks at 37 0C in 5% CO2 68 
until 60-80% confluence. At this confluence, cells were treated with either SDG or enterolactone 69 
at 0-40 µM up to 48 hrs, at which the cells had reached less than 100% confluence. SDG was 70 
purchased from ChromaDex (Irvine, CA), while enterolactone was purchased from either Sigma-71 
Aldrich (St Louis, Mo) or ChromaDex. SDG or enterolactone was dissolved in DMSO and then 72 
mixed with fresh media to achieve the final concentrations. DMSO was kept less than 0.2% in 73 
the final treatment, which did not alter cell growth or cell cycle measurements when compared 74 
with DMSO-free media (data not shown). After treatment, the cells were detached and counted 75 
by hemacytometer as described by our previous publication [9]. 76 
2.2. Cytotoxicity assay 77 
The cell viability was measured in the adherent cells by trypan blue staining [9]. The 78 
viable cell numbers in the treated cells were compared with that in the vehicle controls. 79 
2.3. Cell cycle analysis 80 
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The cell cycle analysis was done as previously described [9-10]. Briefly, the cells were 81 
fixed in ethanol, centrifuged and then the pellet was resuspended in the phosphate buffer saline 82 
solution at pH 7.4, containing 20 g/L propidium iodide and 5000 U/L of RNase (Promega) at 37 83 
oC for 30 min. DNA flow cytometric analysis (FACSCaliber, Becton Dickinson, Newyork, NJ) 84 
was performed with an excitation at 488 nm and an emission at 630 nm. 85 
2.4. Western blot analysis for cyclin A protein 86 
As described in our previous publication [9], the treated cells were harvested and 87 
suspended in Triton lysis buffer. Protein concentration was measured by the Pierce BCA protein 88 
assay kit (Thermo Fisher Scientific, Rockford, IL), and 30 μg of whole cell protein was 89 
electrophoresed on 12% SDS polyacrylamide gels and transferred to pure nitrocellulose 90 
membrane using semi-dry transfer cell (Trans-blot SD cell, BIO-RAD, Hercules, CA). The 91 
membrane was blocked in TDN buffer at 4 ºC for 1 hr. Then the membrane was incubated 92 
overnight with 1:1,000 dilution of anti-cyclin A and anti-β-actin (Cell Signaling Technology 93 
Inc., Danvers, MA). After washing, the membrane was incubated in anti-IgG of horse-radish 94 
peroxidase-conjugated secondary antibody (1:10,000) (Santa Cruz Biotechnology, Santa Cruz, 95 
CA) for 1 hr. The specific protein band was visualized by applying the Super signal west femto 96 
maximum sensitivity substrate (Thermo Fisher Scientific, Rockford, IL). The band was scanned 97 
and detected by using FlouroChemTM 8800 Advanced Imagine System (Alpha Innotech, San 98 
Leandro, CA). The cyclin A protein levels at 55-kDa were normalized as ratios of the density of 99 
β-actin at 43-kDa in the same sample and then presented as the percentages of the vehicle 100 
controls. 101 
2.5. HPLC quantification of SDG and enterolactone 102 
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HPLC-UV quantification of SDG and enterolactone was done according to previous 103 
methods [1, 9] with slight modification. Generally, the cell culture medium was separated by 104 
centrifugation at 1000 X g for 10 min from the treated cells after treatment with 0-40 µM SDG 105 
or enterolactone for 48 hrs.  SDG and enterolactone were analyzed by HPLC using a C18 106 
column (5 µm, 250 X 4.6 i.d. mm, Alltech, Deerfield, Il), eluted with a 5% acetonitrile in 0.01 107 
mM phosphate buffer, pH 2.8 (solvent A) over 100% acetonitrile (solvent B) at a flow rate of 1 108 
mL/min. A gradient runs at 0% solvent B for 10 min, 0-100% solvent B for 20 min, and 100% 109 
solvent B for 10 min.  Peaks were detected by UV-monitoring at 283 nm. The enterolactone and 110 
SDG peak was identified according to both retention time and spectrum by comparison with a 111 
commercial standard, respectively. A linear HPLC calibration curve for both lignans was 112 
obtained for the concentrations between 0 and100 µM.  113 
2.6. HPLC-MS/ESI analysis of intracellular levels of SDG and enterolactone 114 
The SW480 cells treated with 40 µM SDG or enterolactone for 48 hr were harvested by 115 
detaching with trypsin-EDTA as previously described [9] and centrifuged at 1000 X g for 10 116 
min. The supernatant was discarded and the pellet was washed by three times and resuspended in 117 
0.01 M phosphate buffered saline at pH 7.4.  The resulting solution was homogenized under an 118 
ice bucket followed by three 1:1 diethyl ether extractions. The upper organic layer containing the 119 
lignans was evaporated to dryness in a water bath set at 35 ºC under vacuum condition. The 120 
residue remaining at the bottom of the flask was re-dissolved in 100% methanol and ultra-121 
centrifuged at 40,000 X g for 30 minutes. HPLC-MS/ESI analysis was performed with an 122 
Esquire 3000 plus mass spectrometer (Bruker Daltonics, GmbH, Billerica, MA) coupled to an 123 
Agilent (Agilent, Waldbronn, Germany) 1100 series HPLC system. Separations were achieved 124 
with a Synergi Max-RP (Phenomenex, Torrance, CA) column (20 x 2 mm i.d., 2 µm) with a 125 
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linear 2.5 min. gradient from 30-95% acetonitrile in water containing 0.1% formic acid. The 126 
MS/ESI spectra were acquired in positive ionization mode from m/z 100 to1000. The mass 127 
spectrometry instrument was controlled by the esquire control 5.3 software (Bruker Daltonics, 128 
GmbH, Billerica, MA). The data were processed with Data analysis 3.3 software (Bruker 129 
Daltonics, GmbH, Billerica, MA). 130 
2.7. Statistical analyses 131 
All data was analyzed by the SAS statistical system, version 8.2.  The cell number, cell 132 
cycle and HPLC data were analyzed by 2-way ANOVA using a general linear model procedure 133 
followed by Fisher’s protected least square difference. The relationship between lignan 134 
concentrations remaining in cell culture media and the original lignan amounts was determined 135 
by linear regression by using the Pearson’s correlation coefficients (r). The results are present as 136 
means ± SEM and a probability at < 0.05 is considered significantly. 137 
3. Results 138 
3.1. Cell growth inhibition 139 
As shown in Figure 2, treatment of SW480 cells with either SDG or enterolactone at 0-40 140 
µM up to 48 hrs resulted in a dose- and time-dependent decrease in cell number when compared 141 
with the vehicle control.  142 
3.2. Cytotoxicity Assay 143 
The cell viability was generally greater than 80% in the adherent cells, and the treated 144 
cells did not differ significantly from the vehicle-treated controls (data not shown). 145 
3.3. Cell cycle Analysis 146 
The treatment of SW480 cells with either SDG or enterolactone at 30-40 μM for either 24 147 
or 48 hrs induced cell cycle arrest at S-phase significantly (Figure 3). As the percentage of cells 148 
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in S-phase increased, the percentage of cells at both G1 and G2/M phases decreased 149 
correspondingly. 150 
3.4. Cyclin A protein levels 151 
The levels of cyclin A protein significantly increased in the cells treated with SDG at 20-152 
40 μM or enterolactone at 40 μM  for 48 hrs when compared to the vehicle control (Figure 4). 153 
3.5. Stability of SDG vs. enterolactone in the medium 154 
The concentrations of SDG and enterolactone in the cell culture media after treatment 155 
were measured over the time by HPLC method. Figure 5A showed a representative HPLC 156 
chromatograph of the standard SDG with two common SDG metabolites, i.e., enterodiol and 157 
enterolactone. The retention times of SDG, enterodiol, and enterolactone are 20.5, 25.4, and 28.6 158 
min, respectively. By using this established HPLC method, either enterolactone or SDG was 159 
detectable in the media after treatment as shown in Figure 5B and 5C, respectively.  160 
The stability of SDG and enterolactone in the media with or without SW480 cells for 48 161 
hr was further evaluated. As shown in Figure 6, SDG generally exhibited greater stability than 162 
enterolactone in the media with or without the cells. About 95% of SDG at 40 µM in the media 163 
without the cells was detectable after 48 hr treatment verse 57% of enterolactone only. Both 164 
SDG and enterolactone at 10-40 µM resulted in the greater losses in the presence of SW480 165 
cells, likely due to uptake and/or degradation by cellular enzymes. 166 
3.6. Intracellular levels of SDG verse enterolactone 167 
In comparison with the representative HPLC chromatograph of SDG, enterodiol, 168 
enterolactone, and internal standard flavone (Figure 7A), a HPLC chromatograph in Figure 7B 169 
demonstrated a detectable enterolactone from the intracellular extracts of total 210 million cells 170 
Page 10 of 23 
after treatment with enterolactone at 40 μM for 48 hr. However, SDG was not detectable from 171 
the intracellular extracts of the treated cells under a similar condition as shown in Figure 7C.  172 
HPLC detection for both SDG and enterolactone peaks was further identified by MS/ESI 173 
analysis. The representative MS spectra were shown in Figure 8. SDG has a molecular mass at 174 
687 and thus was shown in m/z of 687.02. Furthermore, the ion peak at m/z of 704.09 could be 175 
interpreted as a combination of SDG with a molecule of water [SDG+H2O]+, and the ion peak at 176 
m/z of 709.08 is most likely the sodium salt of SDG [SDG+Na]+. The major ion identified as 177 
enterolactone had a mass/charge ratio of m/z at 298.46 (Figure 8B).  178 
4. Discussion 179 
Lignans are a group of the phytochemicals that compose of phenylpropane dimer linked 180 
by β-β bonds with a 1,4-diarylbutane structure, which are present abundantly in flaxseed, but 181 
also present in various grains such as wheat [9-10]. The most prominent lignan in dietary grains 182 
is SDG. When ingested, SDG undergoes bacterial fermentation to generate lignan mammalian 183 
metabolites, i.e., enterodiol and enterolactone [10]. Although both enterodiol and enterolactone 184 
have been shown for cancer preventive activities, little information is available about the 185 
potential cancer preventive property of SDG by itself. The absorption of mammalian lignans is 186 
usually poor, resulting in a low range of nM up to a few μM in the human plasma and/or urine 187 
samples [19]. However, lignan precursors-enriched foods may reach to the gut and provide a 188 
much high dose into the colonic contents. Bach Knudsen et al. once reported that the mammalian 189 
lignans could be detected up to 175 μmol/kg fecal samples in the stool of pigs fed rye based diets 190 
containing total lignans at 137 μmol/d [20], indicating that a much high dose of dietary lignans 191 
could be physiologically achieved in the colonic contents. Although the physiological 192 
significance of such high doses of lignans presented in the colonic contents is not defined, we 193 
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hypothesized that dietary SDG, in addition to be a precursor of enterodiol and enterolactone, 194 
might influence the colonic mucosal cells in situ. Furthermore, a rational plan for using the 195 
concentrations up to 40 μM tested in this study was also supported. 196 
In this study, we demonstrate that SDG inhibits colon cancer cell growth by inducing S-197 
phase cell cycle arrest, a characteristic previously attributable mostly to its metabolites. In 198 
addition, not only does SDG inhibit colon cancer growth but it is also much more stable than 199 
enterolactone in the cell culture media.  200 
When we reject our hypothesis that SDG might provide different effect on cancer cell 201 
growth when compared with its metabolite entrolantone, we found the effects of SDG and 202 
enterolactone on the cell growth, cell viability, and cell cycle arrest are comparable. However, a 203 
higher stability of SDG in the media than enterolactone may be related to the nature of chemical 204 
structure and the chemical groups attached. The bulky glucose moieties in the SDG structure 205 
may prevent attack from the possible electrophiles in the cell culture media. In addition, the 206 
presence of two methoxy groups attached to outer carbon benzene rings in the SDG structure 207 
may allow for an increased electron delocalization, and hence could be more stable in the 208 
inherent SDG structure [21].  This notion is consistent with the observation that SDG was stable 209 
in the bread products during baking [22]. On the other hand, the reactive lactone group on 210 
enterolactone tends to be unstable as reported in antibacterial studies by using lactone functional 211 
groups [23, 24]. In addition, the accessibility of enterolactone functional groups to the potential 212 
electrophiles appears high. Although, ChemDraw ultra software predicts a negative overall 213 
enthalpy on the enterolactone structure [25], the lactone functional group and the openness of the 214 
enterolactone structure may tend to overshadow this effect towards increased enterolactone 215 
instability. 216 
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It is a challenge to detect intracellular levels of a phytochemical such as lignans. Based 217 
upon our previous experience in flavonoid apigenin [26] and lignan analysis [9-10, 27], HPLC 218 
method is usually sensitive at nanograms per million cells. By collecting over 210 million cells 219 
from a total of 21 cell culture flasks, the intracellular levels of enterolactone in enterolactone-220 
treated cells were indeed measurable. HPLC-MS/ESI further confirmed enterolactone as a 221 
molecular ion with m/z at 298.47. However, the intracellular levels of SDG were not detectable, 222 
nor the common metabolites enterodiol and enterolactone, in SDG-treated cells. Some novel 223 
metabolites were revealed by MS/ESI, but we limited to identify the chemical structures for 224 
those potential metabolites in this moment. Although SDG and/or its metabolites were not 225 
detectable in the treated cells, it should be noted that it was not expected for intact SDG to be 226 
absorbed, since a phytochemical glycoside is usually deglycosilation by β-glucosidase or lactase 227 
phlorozin hydrolase [28]. Therefore, SDG-treated cells with undetectable intracellular SDG or its 228 
currently known metabolites observed in this study may provide novel insight into SDG 229 
metabolism and bioavailability if exposed directly to the colonic cells before degradation by 230 
microorganisms in human gut. 231 
In conclusion, SDG displayed significant anticancer effects as indicated by the inhibition 232 
of colon cancer cell growth. This effect was associated partly with the induction of cell cycle 233 
arrest at S-phase. Also, the stability of SDG is much higher in the cell culture media than 234 
enterolactone. Intracellular level studies revealed that enterolactone taken up by enterolactone-235 
treated cells, but not SDG as it was undetectable in SDG-treated cells. The reliable stability and 236 
undetectable intracellular SDG in treated cells may suggest a metabolism of SDG, if exposed 237 
directly to the colonic cells, could be different from the currently known degradation by 238 
microorganisms in human gut. 239 
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Figure Legends 
Figure 1. Chemical structures of the secoisolariciresinol diglucoside (SDG) verse its 
mammalian metabolite enterolactone. 
Figure 2. Comparison of treatment with SDG verse enterolactone in SW480 cells for 
growth inhibition. The cells were co-cultured with either SDG or enterolactone at 0-40 µM for 
24-48 hrs. The cell number was counted by hemacytometer. The results are present as Means ± 
SEM from 8-11 independent experiments. Means with different superscripts differ significantly, 
P ≤ 0.05. 
Figure 3. Comparison of treatment with SDG verse enterolactone for cell cycle arrest. The 
cells were co-cultured with either SDG or enterolactone at 0-40 µM for 24-48 hrs. The cell cycle 
analysis was performed by DNA flow cytometry. Results are present as Means ± SEM from 5-7 
independent experiments for SDG treatment and 3-4 independent experiments for enterolactone 
treatment.  Means with different superscripts differ significantly, P ≤ 0.05. 
Figure 4. Effects of SDG verse enterolactone on the levels of cyclin A protein. The cells were 
co-cultured with either SDG or enterolactone at 0-40 µM for 48 hrs. The levels of cyclin A 
protein, as measured by Western blotting, significantly increased in the cells treated with SDG at 
20-40 μM or enterolactone at 40 μM when compared to the vehicle control. Values are Mean ± 
SEM from 3 independent experiments. Means with different superscripts are significantly 
different, P ≤ 0.05.  
Figure 5. Representative HPLC chromatograph of SDG treatment verse enterolactone at 
40 µM for 48 hrs in the cell culture media. Panel A: HPLC chromatograph of commercial 
standard SDG, enterodiol, and enterolactone; Panel B: HPLC chromatograph of enterolactone-
treated medium; Panel C: HPLC chromatograph of SDG-treated medium. 
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Figure 6. Stability of SDG verse enterolactone in the media with or without the cells. Either 
SDG or enterolactone was co-cultured at 40 µM in the media without cells or 0-40 µM with 
SW480 cells for 48 hrs. The levels of SDG or enterolactone in the medium extract with or 
without the cells were determined by HPLC method. Results are present as Means ± SEM from 
3-4 independent experiments, *P ≤ 0.05 vs. SDG treatment. 
Figure 7. Representative HPLC chromatograph of SDG treatment verse enterolactone in 
the intracellular extracts. Panel A: HPLC chromatograph of commercial standard SDG, 
enterodiol, enterolactone, and internal standard flavone; Panel B: intracellular detection of 
enterolactone in 40 µM of enterolactone-treated cells for 48 hrs; Panel C: HPLC chromatograph 
of intracellular extracts in 40 µM of SDG-treated cells for 48 hrs. 
Figure 8. HPLC-MS/ESI chromatograph of SDG (Panel A) and enterolactone (Panel B).   
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